Actavis in $25bn Forest buy
This article was originally published in Scrip
Executive Summary
Actavis looks set to top its recent buying spree with its largest acquisition yet, with a potential $25bn buy of Forest Laboratories.
| Table |
|---|
Advertisement
Topics
- Therapy Areas
- Gastrointestinal
- Neurology
- Regions
- Asia Pacific
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC024461
Ask The Analyst
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC024461
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.